Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Sales of Investments
Cash received from selling or redeeming investments.
Puma Biotechnology, Inc.NASDAQ: PBYI
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments growth accelerates
Q1 FY2026 sales of investments of $27.34M rose 93.9% year over year, ahead of the +33.1% change in trailing-twelve-month sales of investments. Sequentially, it rose 37.2% from the prior quarter. Over 3 fiscal years it compounded at +56.1% a year.
Context
- Sales of investments amounted to 31.5% of revenue in FY2025, up 7.3 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +93.9% holds above the trailing-twelve-month pace of +33.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 72.02M USD
- Year-over-year change
- +29.0%
- 4-year CAGR
- +27.6%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.02M | +29.0% |
| FY2024 | 2024-12-31 | 55.85M | +222.3% |
| FY2023 | 2023-12-31 | 17.33M | -8.5% |
| FY2022 | 2022-12-31 | 18.94M | -30.3% |
| FY2021 | 2021-12-31 | 27.19M | — |
Sales of Investments vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.1% is the 2nd highest of 9, against a peer median of -12.9%.
- Sales of investments amounts to 37.5% of revenue for PBYI, versus a peer median of 80.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $254.25M USD | -5.8% | -2.5% | — | |
| LTM Mar 2026 | $225M USD | -27.4% | +24.5% | — | |
| LTM Mar 2026 | $223.03M USD | +378.2% | — | — | |
| LTM Jun 2026 | $139.19M USD | -130.9% | -7.5% | 81.9% | |
| LTM Mar 2026 | $125.44M USD | -4.7% | -21.0% | 79.9% | |
| LTM Mar 2026 | $106.52M USD | -20.1% | +1.5% | — | |
| LTM Mar 2026 | $85.26M USD | +33.1% | +56.1% | 37.5% | |
| LTM Mar 2026 | $67.84M USD | +28.1% | -17.5% | 12922.7% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥531.77K CNY | — | -73.0% | — |
| LTM Mar 2026 | $119K USD | -100.4% | -93.0% | 0.2% | |
| LTM Mar 2026 | CA$0 CAD | — | — | — | |
| Peer median (excluding PBYI) | — | -12.9% | -12.5% | 80.9% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| Deferred Income Tax | 0 | 0 | 0 | (7.08M) | 3.25M |
| Stock-Based Compensation | 32.63M | 11.83M | 10.25M | 8.25M | 6.94M |
| Change in Working Capital | (1.31M) | (44.5M) | (17.85M) | (3.54M) | (10.08M) |
| Accounts Receivables | (5.98M) | (7.82M) | (8.37M) | 16.35M | (21.28M) |
| Inventory | (3.66M) | 2.58M | (2.55M) | (1.64M) | 3.21M |
| Accounts Payables | (902K) | (4.73M) | 449K | (1.38M) | (453K) |
| Other Working Capital | 9.23M | (34.52M) | (7.38M) | (16.86M) | 8.45M |
| Other Non-Cash Items | 7.15M | 7M | 1.51M | (519K) | (358K) |
| Operating Cash Flow | 20.65M | (15.83M) | 27.01M | 38.92M | 41.8M |
| Capital Expenditures | 0 | (7M) | (12.64M) | (56K) | (71K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (38.07M) | (4.84M) | (23.81M) | (76.23M) | (108.14M) |
| Sales of Investments | 27.19M | 18.94M | 17.33M | 55.85M | 72.02M |
| Other Investing Activities | 0 | 0 | (12.5M) | 0 | 0 |
| Investing Cash Flow | (10.88M) | 7.1M | (19.13M) | (20.44M) | (36.19M) |
| Debt Repayment | (1.5M) | 0 | 0 | (33.33M) | (44.44M) |
| Common Stock Issued | 0 | 12.5M | 0 | 150K | 130K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (30.43M) | (277K) | 0 | (666K) | (888K) |
| Financing Cash Flow | (31.93M) | 12.22M | 0 | (33.85M) | (45.2M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (22.16M) | 3.5M | 7.88M | (15.37M) | (39.58M) |
| Free Cash Flow | 20.65M | (22.83M) | 14.37M | 38.86M | 41.73M |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.